| | |
Page
|
| |||
| | | | 2 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 14 | | | |
| | | | 14 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 21 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 25 | | | |
| | | | A-1 | | |
|
Proposed Ratio
(Old Common Stock: New Common Stock) |
| |
Percentage Reduction in
Outstanding Common Stock |
| |
Approximate Number of Shares of
Common Stock to be Outstanding after the Reverse Stock Split |
| ||||||
|
2:1
|
| | | | 50% | | | | | | 36,604,070 | | |
|
3:1
|
| | | | 66.67% | | | | | | 24,402,714 | | |
|
4:1
|
| | | | 75% | | | | | | 18,302,035 | | |
|
5:1
|
| | | | 80% | | | | | | 14,641,628 | | |
|
6:1
|
| | | | 83.33% | | | | | | 12,201,357 | | |
|
7:1
|
| | | | 85.71% | | | | | | 10,458,306 | | |
|
8:1
|
| | | | 87.5% | | | | | | 9,151,018 | | |
|
9:1
|
| | | | 88.89% | | | | | | 8,134,238 | | |
|
10:1
|
| | | | 90% | | | | | | 7,320,814 | | |
|
11:1
|
| | | | 90.91% | | | | | | 6,655,286 | | |
|
12:1
|
| | | | 91.67% | | | | | | 6,100,679 | | |
|
13:1
|
| | | | 92.31% | | | | | | 5,631,396 | | |
|
14:1
|
| | | | 92.86% | | | | | | 5,229,153 | | |
|
15:1
|
| | | | 93.33% | | | | | | 4,880,543 | | |
|
16:1
|
| | | | 93.75% | | | | | | 4,575,509 | | |
|
17:1
|
| | | | 94.12% | | | | | | 4,306,362 | | |
|
18:1
|
| | | | 94.44% | | | | | | 4,067,119 | | |
|
19:1
|
| | | | 94.74% | | | | | | 3,853,060 | | |
|
20:1
|
| | | | 95% | | | | | | 3,660,407 | | |
|
21:1
|
| | | | 95.24% | | | | | | 3,486,102 | | |
|
22:1
|
| | | | 95.45% | | | | | | 3,327,643 | | |
|
23:1
|
| | | | 95.65% | | | | | | 3,182,963 | | |
|
24:1
|
| | | | 95.83% | | | | | | 3,050,340 | | |
|
25:1
|
| | | | 96.00% | | | | | | 2,928,326 | | |
|
26:1
|
| | | | 96.15% | | | | | | 2,815,698 | | |
|
27:1
|
| | | | 96.30% | | | | | | 2,711,413 | | |
|
28:1
|
| | | | 96.43% | | | | | | 2,614,577 | | |
|
29:1
|
| | | | 96.55% | | | | | | 2,524,419 | | |
|
30:1
|
| | | | 96.67% | | | | | | 2,440,272 | | |
|
31:1
|
| | | | 96.77% | | | | | | 2,361,553 | | |
|
32:1
|
| | | | 96.88% | | | | | | 2,287,755 | | |
|
33:1
|
| | | | 96.97% | | | | | | 2,218,429 | | |
|
34:1
|
| | | | 97.06% | | | | | | 2,153,181 | | |
|
35:1
|
| | | | 97.14% | | | | | | 2,091,662 | | |
|
36:1
|
| | | | 97.22% | | | | | | 2,033,560 | | |
|
37:1
|
| | | | 97.30% | | | | | | 1,978,599 | | |
|
38:1
|
| | | | 97.37% | | | | | | 1,926,530 | | |
|
39:1
|
| | | | 97.44% | | | | | | 1,877,132 | | |
|
40:1
|
| | | | 97.50% | | | | | | 1,830,204 | | |
|
Proposed Ratio
(Old Common Stock: New Common Stock) |
| |
Percentage Reduction in
Outstanding Common Stock |
| |
Approximate Number of Shares of
Common Stock to be Outstanding after the Reverse Stock Split |
| ||||||
|
41:1
|
| | | | 97.56% | | | | | | 1,785,565 | | |
|
42:1
|
| | | | 97.62% | | | | | | 1,743,051 | | |
|
43:1
|
| | | | 97.67% | | | | | | 1,702,515 | | |
|
44:1
|
| | | | 97.73% | | | | | | 1,663,822 | | |
|
45:1
|
| | | | 97.78% | | | | | | 1,626,848 | | |
|
46:1
|
| | | | 97.83% | | | | | | 1,591,482 | | |
|
47:1
|
| | | | 97.87% | | | | | | 1,557,620 | | |
|
48:1
|
| | | | 97.92% | | | | | | 1,525,170 | | |
|
49:1
|
| | | | 97.96% | | | | | | 1,494,044 | | |
|
50:1
|
| | | | 98.00% | | | | | | 1,464,163 | | |
|
51:1
|
| | | | 98.04% | | | | | | 1,435,454 | | |
|
52:1
|
| | | | 98.08% | | | | | | 1,407,849 | | |
|
53:1
|
| | | | 98.11% | | | | | | 1,381,286 | | |
|
54:1
|
| | | | 98.15% | | | | | | 1,355,707 | | |
|
55:1
|
| | | | 98.18% | | | | | | 1,331,058 | | |
|
56:1
|
| | | | 98.21% | | | | | | 1,307,289 | | |
|
57:1
|
| | | | 98.25% | | | | | | 1,284,354 | | |
|
58:1
|
| | | | 98.28% | | | | | | 1,262,210 | | |
|
59:1
|
| | | | 98.31% | | | | | | 1,240,816 | | |
|
60:1
|
| | | | 98.33% | | | | | | 1,220,136 | | |
|
61:1
|
| | | | 98.36% | | | | | | 1,200,134 | | |
|
62:1
|
| | | | 98.39% | | | | | | 1,180,777 | | |
|
63:1
|
| | | | 98.41% | | | | | | 1,162,034 | | |
|
64:1
|
| | | | 98.44% | | | | | | 1,143,878 | | |
|
65:1
|
| | | | 98.46% | | | | | | 1,126,280 | | |
|
66:1
|
| | | | 98.48% | | | | | | 1,109,215 | | |
|
67:1
|
| | | | 98.51% | | | | | | 1,092,659 | | |
|
68:1
|
| | | | 98.53% | | | | | | 1,076,591 | | |
|
69:1
|
| | | | 98.55% | | | | | | 1,060,988 | | |
|
70:1
|
| | | | 98.57% | | | | | | 1,045,831 | | |
|
71:1
|
| | | | 98.59% | | | | | | 1,031,101 | | |
|
72:1
|
| | | | 98.61% | | | | | | 1,016,780 | | |
|
73:1
|
| | | | 98.63% | | | | | | 1,002,852 | | |
|
74:1
|
| | | | 98.65% | | | | | | 989,300 | | |
|
75:1
|
| | | | 98.67% | | | | | | 976,109 | | |
| |
The Board unanimously recommends that you vote “FOR” the approval of the
Reverse Stock Split Proposal. |
| |
| |
The Board unanimously recommends that you vote “FOR” the
approval of the Adjournment Proposal. |
| |
Name and Address of Beneficial Owner
|
| |
Shares of
Common Stock Beneficially Owned |
| |
Shares of
Series D Preferred Stock |
| |
Percentage of
Common Stock |
| |
Percentage of
Series D Preferred Stock(13) |
| ||||||||||||
5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | | | |
Entities affiliated with Longitude Venture Partners(1)
|
| | | | 5,411,860 | | | | | | 5,411.860 | | | | | | 7.39% | | | | | | 7.39% | | |
Entities affiliated with Lagunita(2)
|
| | | | 4,570,403 | | | | | | 4,570.403 | | | | | | 6.24% | | | | | | 6.24% | | |
Directors and Named Executive Officers:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Mark Iwicki(3)
|
| | | | 2,650,729 | | | | | | 120.882 | | | | | | 3.50% | | | | | | * | | |
Todd Bazemore(4)
|
| | | | 727,724 | | | | | | 60.161 | | | | | | * | | | | | | * | | |
Kim Brazzell, Ph.D.(5)
|
| | | | 777,015 | | | | | | 226.227 | | | | | | 1.05% | | | | | | * | | |
Mark S. Blumenkranz, M.D.(6)
|
| | | | 4,709,512 | | | | | | 4,709.512 | | | | | | 6.43% | | | | | | 6.43% | | |
Andrew I. Koven(7)
|
| | | | 59,880 | | | | | | — | | | | | | * | | | | | | * | | |
C. Daniel Myers(8)
|
| | | | — | | | | | | — | | | | | | * | | | | | | * | | |
Robert Paull(9)
|
| | | | 49,281 | | | | | | 2.361 | | | | | | * | | | | | | * | | |
Gregory D. Perry(10)
|
| | | | 46,920 | | | | | | — | | | | | | * | | | | | | * | | |
Howard B. Rosen(11)
|
| | | | 98,230 | | | | | | 13.064 | | | | | | * | | | | | | * | | |
All current executive officers and directors as a group (12 persons)(12)
|
| | | | 10,490,749 | | | | | | 5,519.474 | | | | | | 13.42% | | | | | | 7.54% | | |
| | | | KALA PHARMACEUTICALS, INC. | | ||||||
| | | | By: | | |
|
| |||
| | | | | | | Name: | | | | |
| | | | | | | Title: | | | | |